Roche Holding Ltd · SIX:RO
Roche — Barclays Miami Global Healthcare Conference 2020
16 slides from Roche's conference presentation, March 2020
Slide 1: Barclay's Miami Global Healthcare Conference – March 2020
Barclay’s Miami Global Healthcare Conference – March 2020 Late Stage Immunology, Ophthalmology and Infectious Disease Cristin Hubbard | Senior Vice President Immunology, Infectious Disease & Ophthalmology, Global Product Strategy
Slide 2: Forward-looking statements disclaimer
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, str
Slide 3: Strong short term news flow
Strong short term news flow Diversifying the late stage pipeline and setting new standards of care Product Timing Product Filing date risdiplam in SMA Filed for Type 1/2/3 Tecentriq in 1L HCC Filed satralizumab in NMOSD Filed Tecentriq in neoadj TNBC 2020 Ph II & III ongoing; Tecentriq in 1L melanom
Slide 4: Creating new opportunities across therapeutic areas
Creating new opportunities across therapeutic areas Immunology, Ophthalmology and Infectious Disease Etrolizumab Gazyva Xolair Port Delivery Faricimab Xofluza Gut-selective anti-- Xolair blocks Long-acting Bispecific CAP-dependent Type II anti-CD20 β7 integrin with IgE-mediated delivery of antibody
Slide 5: Significant unmet need for improved efficacy in moderate to severe IBD
There is significant unmet need for improved efficacy in moderate to severe IBD Low Remission Rates with UC Standard of Care 100% Induction Maintenance % patients in remission (8-12 weeks) (52 weeks) Many patients lose response over time 50% 35% TNF-naïve patients 20% 10% TNF-IR patients 5% Sustaine
Slide 6: Etrolizumab: First dual-action anti-integrin targeting α4β7/αEβ7
Etrolizumab: First dual-action anti-integrin targeting α4β7/αEβ7 Targets two sources of inflammation – potential for best in class efficacy Etrolizumab dual blockade of α4β7 and αEβ7 Vedolizumab binds α4β7 only Adapted from Marsal J, Agace WW. J Int Med. 2012;272(5):411-429; Vermeire S et al. Lancet
Slide 7: Etrolizumab Phase 3 Program in UC and Crohn's Disease
Etrolizumab Phase 3 Program in UC and Crohn’s Disease A landmark program designed to generate compelling claims Etrolizumab Phase 3 Development Program Comprehensive IBD Dataset ULCERATIVE COLITIS • 8 clinical studies HIBISCUS I: Induction trial comparing etro vs. adalimumab vs placebo in anti-TNF n
Slide 8: Gazyva for Lupus Nephritis
Gazyva for Lupus Nephritis A serious condition with high unmet medical need Lupus nephritis Gazyva (glycoengineered anti-CD20 Mab) Greater b-cell depletion may improve efficacy 500k patients1 globally with lupus nephritis Type II anti-CD20 region: • Increased direct cell death • Decreased CDC • Redu
Slide 9: Gazyva - Positive Phase II results in lupus nephritis
Gazyva - Type II anti-CD20 Positive Phase II results in lupus nephritis Ph II (NOBILITY) results • Ph II (NOBILITY) met both primary and key secondary endpoints and provided clinically meaningful benefits through Week 76 • Rapid and complete peripheral b-cell depletion was achieved and sustained thr
Slide 10: Continuing to invest in Xolair
Continuing to invest in Xolair New indications and patient convenience New Indications & Ease of Use Food Allergy • Food Allergy - high unmet need • Allergen avoidance is only partially effective - Affects > 4.8 million children in US with no - US: Every 3 minutes, someone goes to ER due to an adver
Slide 11: Real world outcomes in neovascular AMD have room for improvement
Real world outcomes have significant room for improvement in patients with neovascular AMD nAMD treatment frequency in real world1 Number of injections correlates with vision improvement1 6 8,000 N=49,485 5 <25% received Vision Change (letters) 7,000 4 10+ injections 6,000 3 # of eyes 5,000 2 4,000
Slide 12: Ophthalmology franchise: Upcoming NME results in 2020
Ophthalmology franchise: Upcoming NME results in 2020 Opportunity to build a global business Port Delivery System in nAMD, DME and DR Faricimab in nAMD, DME and RVO • Refillable intraocular implant using anti-Ang2 anti-VEGF proprietary needle assembly • First bispecific binding simultaneously • Redu
Slide 13: Faricimab and PDS address key unmet needs in nAMD and diabetic eye disease
Faricimab and PDS address key unmet needs in nAMD and diabetic eye disease Opportunity to differentiate on durability of response and efficacy faricimab potential to improve on efficacy Efficacy (BCVA change, letters) anti-VEGF faricimab Port Delivery System 10 potential to improve with ranibizumab
Slide 14: Xofluza - Unique MOA: Opportunity for broad development program
Xofluza - Unique MOA: Opportunity for broad development program Single dose studied across variety of patient types and clinical settings Adhesion Unique MOA Broad Clinical Program Membrane Xofluza fusion Xofluza blocks viral mRNA transcription by inhibiting Continuing to advance the science and add
Slide 15: Key data readouts 2019-2021
Creating new opportunities across therapeutic areas Immunology, Ophthalmology and Infectious disease key data readouts 2019 2020 2021 Gazyva Lupus Nephritis Etrolizumab UC Xolair Food Allergy ✅ HICKORY, HIBISCUS I & II OUtMATCH Nobility Xolair Nasal Polyps Etrolizumab UC Etrollzumab CD ✅ LAUREL, GAR
Slide 16: Doing now what patients need next
Doing now what patients need next
Roche Holding — Barclays Miami Global Healthcare Conference 2020 on 6ix